Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. for the month of May 2023. The filing, dated May 18, 2023, serves primarily to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant is headquartered in Geneva, Switzerland, and files annual reports on Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a financial statement containing quantitative performance data.
Material Changes
No material financial changes versus prior periods are detailed in the text of this filing. The document references an attached press release for specific updates but does not summarize those changes within the Form 6-K body.
Guidance, Outlook, and Risks
The filing does not contain management commentary, guidance, outlook, or risk factors. It notes that the attached press release is incorporated into the company's registration statements on Form F-3 and Form S-8.
Key Facts for Investor Verification
- Review the attached press release (Exhibit 99.1) for the specific corporate announcement made on May 18, 2023.
- Verify the content of the press release as it is incorporated into active registration statements (Form F-3 No. 333-255089 and Form S-8 No. 333-255124).
- Note that this filing contains no standalone financial data or operational metrics.